This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Sutent® (sunitinib malate) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

SUTENT Resources for your Patients

mRCC Materials

SUTENT (sunitinib malate) is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (mRCC) in adults.1

Click 'Download' to browse the content and if this is of interest,  please visit Medisa to request printed materials.

Patient Brochure (mRCC)

Treatment Information booklet

Treatment information booklet, offering guidance and support for your patient’s treatment with SUTENT (sunitinib) for the treatment of advanced/metastatic renal cell carcinoma (mRCC).

Download to browse content Order

Patient Diary (mRCC)

Treatment Diary

Treatment Diary offering guidance and support for your patients  treatment 
with SUTENT (sunitinib). This diary is intended for adult patients prescribed SUTENT for the treatment of advanced/metastatic renal cell carcinoma (mRCC).

Download to browse content Order

Caregivers guide (mRCC)

Carers’ Information Brochure

Carers’ Information Brochure, offering guidance and support for treatment with SUTENT (sunitinib). This booklet is for anyone who is looking after someone who has been prescribed SUTENT to treat metastatic renal cell carcinoma. 

Download to browse content Order

Treatment Tracker (mRCC)

SUTENT Treatment Tracker

SUTENT treatment tracker is a chart that can be used by patients if you would like them to take SUTENT for 4 weeks and then have a 2-week break. This chart is to be used by patients, who have been prescribed SUTENT to ensure that they take their daily dose. 
​​​​​​​
Patients just need to mark the card in the correct place after every dose

Download to browse content Order

GIST and pNET Materials 

SUTENT is also indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance, and unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults.1

GIST Patient Diary

Treatment of Gastrointestinal Stromal Tumours (GIST)

Treatment Diary offering guidance and support for your treatment with SUTENT (sunitinib). This diary is intended for adult patients prescribed SUTENT for the treatment of gastrointestinal stromal tumours (GIST)

Download to browse content Order

GIST Patient Booklet

Treatment Of Gastrointestinal Stromal Tumour

SUTENT  (sunitinib malate) in gastrointestinal stromal tumour information booklet. For patients prescribed SUTENT  (sunitinib malate) for the treatment of gastrointestinal stromal tumour.

Download to browse content Order

pNET Patient Diary 

Treatment Of Pancreatic Neuroendocrine Tumours (pNET)

Treatment Diary offering guidance and support for your treatment 
with SUTENT (sunitinib). This diary is intended for adult patients prescribed SUTENT for the treatment of pancreatic neuroendocrine tumours (pNET). 

Download to browse content Order

pNET Patient Booklet 

Patient Booklet pNET

For patients prescribed SUTENT  (sunitinib malate) for the treatment of pancreatic neuroendocrine tumours (pNET).

Download to browse content Order

Resources

Indication

  • SUTENT (sunitinib malate) is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (mRCC) in adults.

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No